Is there any role for ascertaining somatostatin-receptor status with a DOTATATE PET scan in prostatic adenocarcinoma with neuroendocrine features to consider lanreotide along with chemotherapy?
Answer from: Medical Oncologist at Academic Institution
Great question! The easy answer is no--regarding current standard of care treatments. This is not an FDA-approved treatment. However, this touches on the larger issue of we don't really know/understand what it means 'neuroendocrine' prostate cancer is. Ongoing work is better defining the molecular c...
Sign in or Register to read more